# Merck Sharp and Dohme

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/merck-sharp-and-dohme/

## Facts

| Field | Value |
| --- | --- |
| Country | GB |
| OpenAlex ID | https://openalex.org/F4320332932 |
| Works | 6,864 |

## Funder papers

- [Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes](https://scholariq.org/papers/concurrent-rb1-and-tp53-alterations-define-a-subset-of-egfr-mutant-lung-cancers/)
- [Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/maintenance-olaparib-for-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups](https://scholariq.org/papers/canagliflozin-and-cardiovascular-and-renal-outcomes-in-type-2-diabetes-mellitus/)
- [Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors](https://scholariq.org/papers/genome-wide-profiling-of-non-smoking-related-lung-cancer-cells-reveals-common/)
- [Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial](https://scholariq.org/papers/patient-centred-outcomes-and-effect-of-disease-progression-on-health-status-in/)
- [Examining enablers of vaccine hesitancy toward routine childhood and adolescent vaccination in Malawi](https://scholariq.org/papers/examining-enablers-of-vaccine-hesitancy-toward-routine-childhood-and-adolescent/)
- [High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership](https://scholariq.org/papers/high-incidence-of-proliferative-and-membranous-nephritis-in-sle-patients-with/)
- [Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial](https://scholariq.org/papers/effects-of-canagliflozin-on-myocardial-infarction-a-i-post-hoc-i-analysis-of-the/)
- [Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network](https://scholariq.org/papers/extrarenal-symptoms-associate-with-worse-quality-of-life-in-patients-enrolled-in/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.